Vosevi is a key fixed‑dose combination medication for the treatment of chronic hepatitis C virus (HCV) infection. Mastering its correct dosage and administration, strictly adhering to precautions, and adopting a healthy lifestyle are critical to ensuring therapeutic efficacy and minimizing risks.

I. Dosage and Administration of Vosevi

1. Standard Dosage and Administration

(1) Vosevi is a fixed‑dose combination tablet. Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.

(2) The recommended dosage is one tablet orally once daily, taken with food to enhance drug absorption.

2. Treatment Duration

The treatment duration is 12 weeks for all patients, determined by prior treatment history and HCV genotype:

(1) Patients with HCV genotypes 1, 2, 3, 4, 5, or 6 who have previously received an NS5A inhibitor‑containing regimen: 12 weeks.

(2) Patients with HCV genotype 1a or 3 who have previously received a sofosbuvir‑containing regimen without an NS5A inhibitor: 12 weeks.

3. Dosage Adjustment in Special Populations

(1) Renal impairment: No dosage adjustment is required for patients with any degree of renal impairment, including those on dialysisEuropean Medicines Agency.

(2) Hepatic impairment: No dosage adjustment is needed for patients with mild hepatic impairment (Child‑Pugh A). Vosevi is not recommended for patients with moderate to severe hepatic impairment (Child‑Pugh B or C).

(3) Elderly patients: No dosage adjustment is necessaryEuropean Medicines Agency.

II. Precautions for Vosevi Use

1. Mandatory Hepatitis B Virus (HBV) Screening Before Treatment

(1) Before initiating Vosevi therapy, all patients must be tested for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti‑HBc) to assess the risk of active or prior HBV infection.

(2) For patients co‑infected with HCV and HBV, close monitoring for signs of HBV reactivation is required during and after treatment cessation.

2. Strict Avoidance of Drug Interactions

Vosevi has significant interactions with multiple medications. Consult a healthcare provider before concomitant use:

(1) Absolute contraindication: Rifampin.

(2) Not recommended: Carbamazepine, phenytoin, St. John’s Wort, atazanavir, lopinavir, efavirenz, cyclosporine, rosuvastatin, etc.

(3) Separate administration: Antacids containing aluminum or magnesium should be taken at least 4 hours apart from Vosevi.

(4) Monitoring and adjustment required: Digoxin, dabigatran, warfarin, certain statins, and antidiabetic agents, etc.

3. Vigilance for Severe Adverse Reactions

(1) HBV reactivation: Manifested by a sudden rise in transaminases, jaundice, or liver failure. Seek immediate medical attention.

(2) Hepatic decompensation: Discontinue Vosevi immediately if jaundice, ascites, hepatic encephalopathy, or variceal bleeding occurs.

(3) Bradycardia: May occur with concomitant amiodarone use, presenting as dizziness, syncope, or fatigue. Cardiac monitoring is required.

III. Healthy Lifestyle for Patients Taking Vosevi

1. Adhere to Regular Medication

(1) Take Vosevi with meals at a fixed time daily to establish a routine and avoid missed dosesEuropean Medicines Agency.

(2) Do not discontinue treatment or alter the dosage without medical advice. Completing the full treatment course is critical for viral eradication.

2. Balanced Diet and Nutrition

(1) Take Vosevi with food to reduce gastrointestinal discomfort.

(2) Avoid alcohol consumption, as alcohol increases liver burden and impairs drug metabolism.

(3) Follow a light diet. Avoid greasy and spicy foods if diarrhea or nausea occurs, and ensure adequate hydration.

3. Monitor Health Status

(1) Undergo regular follow‑up tests: liver function, HBV markers (if at risk), blood glucose (for diabetic patients), and INR (for patients taking warfarin).

(2) Seek immediate medical attention if symptoms such as unusual fatigue, yellowing of the skin or sclera, dark urine, bleeding tendency, or altered consciousness occur.

For more detailed information, please refer to the Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) prescribing information.